Personalis, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million initial public offering by Personalis, Inc. The common stock is listed…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…
Orchard Therapeutics plc Approximately $128 Million Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics…
IDEAYA Biosciences, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…
NeoGenomics Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the follow-on offering of 8,050,000 shares of common stock of…
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied…
Bristol-Myers Squibb Company $19 Billion Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $19 billion in aggregate principal amount of senior notes by Bristol-Myers…
Intercept Pharmaceuticals, Inc. Concurrent $231 Million Common Stock Offering and $230 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc. …
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…
Zai Lab Limited $230 Million Follow-On Offering of American Depositary Shares
Davis Polk advised Zai Lab Limited in connection with its follow-on offering of $230 million of American Depositary Shares representing 9,019,608 ordinary shares of the company. The ADSs…